StockNews.AI
SRPT
StockNews.AI
154 days

Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

1. Sarepta initiated an investigation into possible securities fraud. 2. A patient died after treatment with Elevidys, causing a 27% stock drop. 3. Doctors may become cautious about prescribing Elevidys to new patients. 4. The law firm will represent aggrieved investors in potential claims. 5. Investors are encouraged to contact the law firm for recovery options.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The 27% drop indicates significant investor panic. Historical examples show that such events often lead to long-term stock devaluation.

How important is it?

The news directly involves Sarepta and suggests substantial legal and financial repercussions. The potential class action could further exacerbate investor fears and affect the stock price.

Why Short Term?

The immediate impact of investigations and lawsuits typically influences stock prices quickly. Investor sentiments tend to stabilize or deteriorate after legal outcomes are clearer.

Related Companies

PTCTAXSMSPRO
Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, March 18, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRPT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Sarepta investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: info@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. Sarepta Therapeutics' stock plunged by as much as 27% on March 18, 2025, after the company announced that a patient had died following treatment with its gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD). RBC Capital Markets noted that this news could make doctors more cautious when prescribing the medication to new patients. According to Sarepta, the patient suffered from acute liver failure. Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq.Admitted CA, NY and TX Barslesley@portnoylaw.com310-692-8883www.portnoylaw.com Attorney Advertising

Related News